Paul Tudor Jones Bridge Bio Pharma, Inc. Transaction History

Tudor Investment Corp Et Al

$44 Billion
Q2 2025

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 124,068 shares of BBIO stock, worth $6.98 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

124,068

Previous 91,332 35.84%

Holding current value

$6.98 Million

Previous $3.16 Million 69.69%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$30.14 - $45.12 $986,663 - $1.48 Million	32,736 Added 35.84%	124,068 $5.36 Million
Q1 2025 May 15, 2025	BUY	$28.12 - $37.59 $2.57 Million - $3.43 Million	91,332 New	91,332 $3.16 Million
Q1 2024 May 15, 2024	BUY	$27.35 - $40.45 $606,185 - $896,533	22,164 New	22,164 $685,000
Q3 2023 Nov 15, 2023	BUY	$16.89 - $35.01 $1.37 Million - $2.84 Million	81,150 New	81,150 $2.14 Million
Q1 2023 May 15, 2023	SELL	$7.17 - $18.55 $367,010 - $949,518	-51,187 Reduced 68.7%	23,321 $387,000
Q4 2022 Feb 14, 2023	SELL	$6.74 - $11.52 $35,169 - $60,111	-5,218 Reduced 6.54%	74,508 $568,000
Q3 2022 Nov 14, 2022	BUY	$7.94 - $12.36 $633,024 - $985,413	79,726 New	79,726 $792,000
Q1 2022 May 16, 2022	SELL	$7.34 - $17.16 $883,530 - $2.07 Million	-120,372 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$11.38 - $53.41 $337,747 - $1.59 Million	29,679 Added 32.72%	120,372 $2.01 Million
Q3 2021 Nov 15, 2021	BUY	$46.87 - $64.24 $2.04 Million - $2.8 Million	43,630 Added 92.71%	90,693 $4.25 Million
Q2 2021 Aug 16, 2021	BUY	$46.47 - $63.93 $2.19 Million - $3.01 Million	47,063 New	47,063 $2.87 Million

Others Institutions Holding BBIO

# of Institutions

410

Shares Held

187M

Call Options Held

11.3M

Put Options Held

1.91M

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $8.34B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account